Goldstein et al. have assessed the incidence of upper gastrointestinal complications in patients treated with the COX-2-selective inhibitor, valdecoxib. The authors carried out a predefined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback